CF update today
- Thread starter anonymous
- Start date
-
- Tags
- None
Fresenius Medical Care North America might be acquiring the Opko Renal division.
Vifor Fresenius Medical Care Renal Pharma Ltd. is a strategic partnership between Vifor Pharma and Fresenius Medical Care.
To strengthen its position in the global intravenous iron market Vifor Pharma first joined forces with Fresenius Medical Care, the world leader in dialysis products and services in 2008 with exclusive licence agreements for the commercialisation of Venofer® and Ferinject® for iron deficiency anaemia in haemodialysis in the USA, Europe, the Middle East, Africa and Latin America.
In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharmaceuticals company, Vifor Fresenius Medical Care Renal Pharma Ltd02. The new nephrology company develops and commercialises innovative and high-quality products to improve the lives of patients suffering from chronic kidney disease worldwide.
To strengthen its position in the global intravenous iron market Vifor Pharma first joined forces with Fresenius Medical Care, the world leader in dialysis products and services in 2008 with exclusive licence agreements for the commercialisation of Venofer® and Ferinject® for iron deficiency anaemia in haemodialysis in the USA, Europe, the Middle East, Africa and Latin America.
In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharmaceuticals company, Vifor Fresenius Medical Care Renal Pharma Ltd02. The new nephrology company develops and commercialises innovative and high-quality products to improve the lives of patients suffering from chronic kidney disease worldwide.
Through our industry-leading network of more than 2,200 dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, Fresenius Medical Care provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s only vertically integrated renal company, we also offer specialty pharmacy and laboratory services, as well as manufacturing and distributing the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals.
Our integrated approach helps to not only improve patients' health outcomes, but also reduce the total cost of care.
Around the world, we care for more than 290,000 renal patients in our global network of more than 3,400 dialysis clinics. At the same time, we operate more than 40 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
Our strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality.
Fresenius Medical Care’s corporate headquarters is in Bad Homburg, Germany. Our North American headquarters is in Waltham, Massachusetts and our Asian-Pacific headquarters is located in Hong Kong.
Maybe Luitpoid Pharmaceuticals (Diaiichi Sankyo) might acquire the division?
Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, consists of four divisions: American Regent, Regency Therapeutics, Animal Health, and Osteohealth. We are innovators in the development, manufacturing and distribution of products in our chosen areas of specialization, and a reliable partner in providing pharmaceuticals and devices which address diverse medical, dental and veterinary needs. We are committed to quality and our professionals ensure that focus in every step of the manufacturing process – from raw materials procurement to packaging and distribution of our products.
Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, consists of four divisions: American Regent, Regency Therapeutics, Animal Health, and Osteohealth. We are innovators in the development, manufacturing and distribution of products in our chosen areas of specialization, and a reliable partner in providing pharmaceuticals and devices which address diverse medical, dental and veterinary needs. We are committed to quality and our professionals ensure that focus in every step of the manufacturing process – from raw materials procurement to packaging and distribution of our products.
Daiichi Sankyo
The Company’s beginnings date back to 1899. Its history of scientific innovation began shortly thereafter with the discovery of epinephrine – a lifesaving medication still widely used today.
In 1912, the first president of Sankyo, Dr. Jokichi Takamine, organized the gift of 3000 cherry trees from Tokyo’s mayor, Yukio Ozaki,to Washington DC where they bloom every spring to the delight of local citizens and visitors to the U.S. capital.
Daiichi Sankyo Company, Ltd. was established in 2005 through the merger of two leading Japanese pharmaceutical companies; Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Both companies had a great tradition in pharmaceutical research and development and by combining their strengths have become a global pharmaceutical innovator.
This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com
Luitpold Pharmaceuticals, Inc. is proud to be a member company of the Daiichi Sankyo group.
Oh My God. We need more people marketing a new product 60 days into launch . Not less!
Frost is confused about Rayaldee. IT IS NOT SENSPAR and WE ARE NOT AMGEN.
FDA approved Sensipar in March 8th, 2004 - it was a different world back in 2004. Amgen put money into the launch. They had marketing materials, a computer system that work, manageable territories, Medicare Approval (NATIONWIDE),a nd a serious motivating incentive compensation plan. The industry has changed in the last 12 years and Sensipar wasn't launched during a holiday period. MSLs, Market Access and Managed Care was in place MONTHS before the launch of Sensipar. Pharma guidelines didn't really exist in 2004. No sunshine act and spouses could attend programs.
Our NSM was 10/18/16 and there were only THREE days training.
ASN was 11/15/16.
Rayaldee wasn't available in pharmacies until 11/28/16.
9 weeks after product was available, VP cut and inside sales force cut.
WTF?
How safe are our jobs if you are cutting people when we literally began selling this product in Jan. 2017?
Do you not understand the marketplace?
How little do the employees matter if we constantly send up feedback and nothing gets done?
Opko Health is like a drop of sweat on a pimple on Amgen's ass. STOP comparing us to Amgen and expecting results like Amgen. Frost won't supply the resources so we can even play in Amgen's sandbox.
To answer your question "How little do the employees matter if we constantly send up feedback and nothing gets done?" Frost declined to give any severance to the inside team that was cut. Zero. So that shows you how much he cares about employees.
Thanks for the stupid video link Charlie. Are you now our VP of Sales?
With friends like you, who needs enemies?
You know the saying about keeping your friends close and enemies closer?
Doesn't CB look like Judas Iscariot?
With friends like you, who needs enemies?
You know the saying about keeping your friends close and enemies closer?
Doesn't CB look like Judas Iscariot?
Maybe Phil Frost should pay the Salespeople their hardworking ,swimming uphill pay and bonuses and not worry about 100 million to Charity. Pay your people pal. And spend the extra 99 million on some real marketing .
Phil Frost will not pay. When he sells/cuts the renal division there will be no severance for the field team. That's just the way he does business and he won't change. He has been very successful doing business this way so why change his ways? Cut throat but that's the way he is.
Phil never wanted an inside sales force for Rayaldee-- thought selling a drug to nephrologists over the phone was pure dork. This guy DeMarco thinking that a nephrologist would pick up a phone for a voice only presentation from a pharma rep about a brand new drug seems to have misunderstood what a nephrologist thinks of his own time and importance as a doctor. It's almost like a robo call, and Frost never bought into that.. I'm sure DeMarco will do quite well-- he's got 30 yrs under his belt. How his underlings, now terminated do, makes it unfortunate that DeMarco did not understand how important meeting tete a tete with a doctor is, especially when DeMarco's boss is Frost..
Macy's is loosing ground to Amazon. Nobody has time to go in a store when they can quickly order online. Streaming movies is replacing going to the theatre. The in office Detail is being technologically displaced in many areas. The telephone that we all carry 24/7 now is our most important tool. Brokers sell zillions of dollars on Wall St and never meet the client. If you know how to sell on the telephone or in person you can do well. But you need to follow up both presentations with back up material. There is none to hand or send. The product marketing is weak. We can clearly see that. Focus there for our future success..